Antoine Deslandes

ORCID: 0009-0007-6272-7327
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Antibiotics Pharmacokinetics and Efficacy
  • Drug Transport and Resistance Mechanisms
  • Monoclonal and Polyclonal Antibodies Research
  • Pharmaceutical studies and practices
  • Neuroscience and Neuropharmacology Research
  • HER2/EGFR in Cancer Research
  • Biosimilars and Bioanalytical Methods
  • Cancer Treatment and Pharmacology
  • Growth Hormone and Insulin-like Growth Factors
  • Neurotransmitter Receptor Influence on Behavior
  • Bacterial Identification and Susceptibility Testing
  • Radiopharmaceutical Chemistry and Applications
  • Ocular Infections and Treatments
  • Microfluidic and Capillary Electrophoresis Applications
  • Chemical Synthesis and Analysis
  • 3D Printing in Biomedical Research
  • Spectroscopy and Chemometric Analyses
  • Synthesis and Biological Evaluation
  • Essential Oils and Antimicrobial Activity
  • Multiple Myeloma Research and Treatments
  • Neurological disorders and treatments
  • Functional Brain Connectivity Studies
  • Blood groups and transfusion
  • PI3K/AKT/mTOR signaling in cancer
  • Memory and Neural Mechanisms

Sanofi (France)
2007-2023

Bristol-Myers Squibb (United States)
2015

Eli Lilly (United States)
2015

AbbVie (United States)
2015

Biogen (United States)
2015

Amgen (United States)
2015

Novartis (Switzerland)
2015

Pfizer (United States)
2015

GlaxoSmithKline (United Kingdom)
2015

Janssen (United States)
2015

Cationic antimicrobial peptides (CAPs) play important roles in host immune defenses. Plectasin is a defensin-like CAP isolated from the saprophytic fungus Pseudoplectania nigrella. NZ2114 novel variant of plectasin with potent activity against Gram-positive bacteria. In this study, we investigated (i) vivo pharmacokinetic and pharmacodynamic (PK/PD) characteristics (ii) efficacy comparison those two conventional antibiotics, vancomycin or daptomycin, an experimental rabbit infective...

10.1128/aac.00453-11 article EN Antimicrobial Agents and Chemotherapy 2011-08-23

Various approaches to first-in-human (FIH) starting dose selection for new molecular entities (NMEs) are designed minimize risk trial subjects. One approach uses the minimum anticipated biological effect level (MABEL), which is a conservative method intended maximize subject safety and primarily NMEs having high perceived risks. However, there concern that MABEL being inappropriately used lower molecules with negative impacts on drug development time patient access. In addition, ambiguity...

10.1002/cpt.2009 article EN Clinical Pharmacology & Therapeutics 2020-08-05

We studied the action of nifedipine on bioavailability cefixime, a molecule absorbed via gut wall dipeptide carrier system in rat, and D-xylose, which is pH (and Na(+)-)-dependent transporter. Each compound was administered alone or combination with 20 mg to eight healthy male volunteers. Nifedipine significantly increased absorption rate cefixime (20.7 +/- 4.3 versus 16 3.5 mg/h absence nifedipine). The absolute 31% 6% compared 53% 1% (P < 0.01) presence nifedipine. observed peak...

10.1128/aac.36.11.2462 article EN Antimicrobial Agents and Chemotherapy 1992-11-01

Intestinal absorption of aminopenicillins in vitro uses the dipeptide carrier system. Recent experiments have reported calcium ion to be a cellular mediator regulation electrolyte transport through enterocyte membrane, especially Na/H exchange which is partly responsible for proton gradient energizing In order assess vivo relevance these data, we studied, healthy volunteers, influence nifedipine, channel blocking agent, on intestinal uptake amoxicillin, commonly prescribed and well-absorbed...

10.1016/s0022-3565(25)12777-8 article EN Journal of Pharmacology and Experimental Therapeutics 1990-10-01

3582 Background: AVE1642, a humanized mAb, binds the human IGF1R specifically and with high affinity (Kd<1nM). It delays growth of cancer cells in vitro tumors xenografted to nude mice. Materiel Methods: this study aims select dose AVE1642 be combined docetaxel 75 mg/m2 (D). was administered as single agent at cycle(cy)1 then combination D from cy2, q3w. Sequential tumor biopsies were performed subset pts. Main eligibility criteria: ≥ 18y.o; measurable or evaluable advanced ST; PS ≤2;...

10.1200/jco.2008.26.15_suppl.3582 article EN Journal of Clinical Oncology 2008-05-20

Abstract Subcutaneous (subQ) injection is a common route for delivering biotherapeutics, wherein pharmacokinetics largely influenced by drug transport in complex subQ tissue microenvironment. The selection of good candidates with beneficial injections currently limited lack reliable testing models. To address this limitation, we report here Co-Culture Tissue-on-a-chip Injection Simulation (SubCuTIS). SubCuTIS possesses 3D coculture architecture, and it allows facile quantitative...

10.1093/pnasnexus/pgad317 article EN cc-by-nc-nd PNAS Nexus 2023-09-29

Interest in the intestinal absorption mechanisms of drugs has increased because transepithelial passage across gut does not necessarily follow a passive diffusion process. Amoxycillin, like other amino-β-lactamantibiotics, been demonstrated vitro to use dipeptide carrier-mediated system rodent small intestine. In order assess in-vivo relevance these data, we applied Loo-Riegelman methodfor reappraisal amoxycillin kinetics healthy human volunteers. The results showed evidence ofa saturable...

10.1093/jac/27.5.647 article EN Journal of Antimicrobial Chemotherapy 1991-01-01

We compared the effects of nifedipine and diltiazem on uptake cefpodoxime proxetil (CP). The study was aimed at establishing impact increased mesenteric blood flow due to calcium channel blockers passive transport. Twelve volunteers were given CP (200 mg) orally in a crossover design. absorption, disposition, elimination parameters among following three treatment groups: alone, oral administration (60 mg), or (20 mg). No statistically significant difference pharmacokinetic observed between groups.

10.1128/aac.40.12.2879 article EN Antimicrobial Agents and Chemotherapy 1996-12-01

Abstract SAR650984 is a novel humanized monoclonal antibody specifically targeting the CD38. , A phase 1 dose escalation study being conducted in patients with confirmed CD38+ hematological malignancies to determine safety of SAR650984, establish MTD and biologically active dose, characterize PK PD after repeated IV administration. Methods: The design was composed 2 parts. first one an accelerated 3 per cohort from 0.0001 mg/kg 0.1 second includes 7 between 0.3 20 every weeks. An additional...

10.1158/1538-7445.am2014-2908 article EN Cancer Research 2014-10-01
Coming Soon ...